Arbutus Biopharma Corp: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 4, 2018 and accepted by EDGAR at May 3, 2018, 17:37 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-01-01 to 2018-03-31 | $1.4m | us-gaap:Revenues |
| Research and development | 3 months2018-01-01 to 2018-03-31 | $13.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-01-01 to 2018-03-31 | −$18.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-01-01 to 2018-03-31 | $104.0k | us-gaap:InterestExpense |
| Net income | 3 months2018-01-01 to 2018-03-31 | −$17.4m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2018-01-01 to 2018-03-31 | −$20.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2018-01-01 to 2018-03-31 | $248.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-03-31 | $12.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-03-31 | $175.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $270.0m | us-gaap:Assets |
| Current liabilities | At period end2018-03-31 | $10.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-03-31 | $37.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-03-31 | $232.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-18-005886. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.